Veru is trading approximately 5% down today at $2.64 as the stock undergoes a period of consolidation following a recent rally fueled by a Novo Nordisk clinical supply deal and robust Q2 fiscal 2026 earnings.
- Shares are giving back gains after a sharp move higher, driven primarily by short-term profit-taking and technical consolidation.
- Broader biotech sector weakness and a risk-off mood across equities are contributing to the selling pressure, though company-specific cooling remains the primary driver.